TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03414125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT Screening Strategy
Description: Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice Screening Strategy
Description: Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up.
Study: NCT00705822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Estramustine + Hydrocortisone
Description: Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel + Prednisone
Description: Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
Study: NCT02503930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: In this group subjects will receive 20 min of treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In this group subjects will receive 20 min of sham stimulation.
Study: NCT04426162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-domain Intervention
Description: Intervention includes neurofeedback, heart rate variability biofeedback, memory and cognitive training, and one-on-one coaching to encourage behavior change in diet, sleep, physical fitness, and stress reduction.
Study: NCT01864694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC-Diet
Description: Participants receive diet intervention through an automated telephone system

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB-Diet
Description: Participants receive diet intervention through a web-based system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment-only control
Description: Assessment-only control
Study: NCT01846143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pBCAR3-phosphopeptide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pIRS2-phosphopeptide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
Study: NCT04038398

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-invasive ventilation with different FiO2 settings
Description: CPAP therapy applied with different order of FiO2 settings.
Study: NCT03406195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS paradigm called theta burst stimulation
Study: NCT04889677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01050660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fat emulsion
Description: An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restriction of intravenous fat emulsion to 1 gm/kg/d
Description: Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
Study: NCT01466751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study: NCT04359953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 2 x per day during 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 2 x per day during 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 2 x per day during 14 days
Study: NCT00852644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Standard CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Standard CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Standard CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Standard CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Standard CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Standard CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: standard doses with CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: standard doses with CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: standard doses with CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: standard doses with CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: standard doses with CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: standard doses with CT scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 4 doses over 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 4 doses over 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 4 doses over 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 4 doses over 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 4 doses over 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 4 doses over 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: CyberKnife radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: CyberKnife radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: CyberKnife radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: CyberKnife radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: CyberKnife radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: CyberKnife radiosurgery
Study: NCT03088241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: switch
Description: switch to second-line ART
Study: NCT03255278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single GamTBvac vaccination (0.25 dose)
Description: Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double GamTBvac vaccination (0.25 dose)
Description: Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double GamTBvac vaccination (0.5 dose)
Description: Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double GamTBvac vaccination (1.0 dose)
Description: Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
Study: NCT00783510

Intervention type: BIOLOGICAL
Intervention: adalimumab
Description: As prescribed by treating physician

Intervention type: DRUG
Intervention: Methotrexate
Description: As prescribed by treating physician
Study: NCT04150432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edmon
Description: New device for exhaled propofol concentration measurements
Study: NCT01557010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: Tablets, oral administration, 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: Tablets, oral administration, 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: Tablets, oral administration, 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Tablets, oral administration, Placebo
Study: NCT02413983

Intervention type: PROCEDURE
Intervention: hepatectomy conventional incision
Description: This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision

Intervention type: PROCEDURE
Intervention: hepatectomy midline incision

Intervention type: PROCEDURE
Intervention: hepatectomy transverse incision
Study: NCT00984789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)
Description: 0.55mg ethinylestradiol and 2.1mg gestodene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norelgestromin/Ethinylestradiol (EVRA)
Description: 0.6mg ethinylestradiol and 6mg norelgestromin
Study: NCT01057628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT03095703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
Study: NCT01617486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BALANCE
Description: The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
Study: NCT01401140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: St Thomas
Description: Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol
Description: Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
Study: NCT03095105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg BIA 6-512
Description: capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg BIA 6-512
Description: capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
Study: NCT01962454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated Water
Description: D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deuterated Water
Description: D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
Study: NCT01962454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Description: Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match testosterone enanthate
Description: Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
Study: NCT01733355

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18] T807
Description: Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
Study: NCT00003248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT00148239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Only Intervention
Description: A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Treatment
Description: Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants given written educational materials at beginning of study; no treatment beyond this
Study: NCT03928470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EsoDuo Tab. 20/800mg
Description: Nexium Tab. 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EsoDuo Tab. 20/800mg
Description: Nexium Tab. 20mg
Study: NCT03085069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study: NCT02424669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALS Functional rating Scale-revised (ALS FRS-R)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALS Functional rating Scale-revised (ALS FRS-R)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slow vital capacity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slow vital capacity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebrospinal Fluid (CSF) sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebrospinal Fluid (CSF) sample
Study: NCT01137630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K40a
Description: One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K40b
Description: One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
Study: NCT02523586

Intervention type: OTHER
Intervention: Oxygen administration
Description: Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
Study: NCT00446394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources and Activities for Life Long Independence (RALLI)
Description: Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Walking program (SW)
Description: Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
Study: NCT01827501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulsioflexTM Monitoring
Description: Fluid and catecholamine management according to PulsioflexTM measurements
Study: NCT02061995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREOB® Intravenous Infusion
Description: Each patient will undergo a single intravenous administration of PREOB®.
Study: NCT02221076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE)
Description: Real-time microscopic imaging of living tissue during the standard procedure
Study: NCT02935738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Description: Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Description: Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
Study: NCT01435993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: Intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: placebo intravenous infusion
Study: NCT00622934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Description: 300mg/kg erythropoietin 3 times on the first week of admission

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04072770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea
Description: Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Description: Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.